Usefulness of PET-guided surgery with 64Cu-labeled cetuximab for resection of intrapancreatic residual tumors in a xenograft mouse model of resectable pancreatic cancer
Conclusions OpenPET-guided surgery with 64Cu-labeled-cetuximab enabled intraoperative identification and resection of intrapancreatic small residual tumors. This technology could be useful to prevent tumor residuals during surgery and improve pancreatic cancer survival.
Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):e103. doi: 10.1016/j.ijrobp.2021.07.500.ABSTRACTPURPOSE/OBJECTIVE(S): Nodal staging systems vary substantially across solid tumors, which implies significant heterogeneity in the behavior of nodal variables across cancers. We hypothesized, in contradiction to this, that quantitative metastatic lymph node (LN) burden is a universal and dominant predictor of mortality across solid cancers, and therefore is capable of both simplifying and improving nodal staging for many cancers.MATERIALS/METHODS: Retrospective cohort analysis of 1,304,498 patients in the National Cancer Databa...
CONCLUSION: Tumor expression of SMAD4 is significantly associated with better clinical outcome, specifically lower DM and higher DFS and OS, in tumor samples from a large, phase III randomized trial of resectable pancreatic cancer.PMID:34700492 | DOI:10.1016/j.ijrobp.2021.07.327
A new study finds that cases of pancreatic cancer increased among both men and women between 2000 and 2018, particularly among women 15 to 34 years of age, and it's not clear why.Reuters Health Information
Early research suggests one-stop radiotherapy after surgery may"improve local control of pancreatic cancer."Medscape Medical News
Condition: Pancreatic Cancer Interventions: Drug: Pembrolizumab; Drug: Olaparib Sponsors: Cambridge University Hospitals NHS Foundation Trust; National Institute for Health Research, United Kingdom Not yet recruiting
Cancer Biol Ther. 2021 Oct 25:1-5. doi: 10.1080/15384047.2021.1991739. Online ahead of print.ABSTRACTMetastatic pancreatic adenocarcinoma (PDAC) is a rapidly lethal disease, with less than half of patients surviving 12 months, and 5-year survival approximately 3%. These outcomes are in large part due to a lack of effective medical and surgical therapies for metastatic PDAC. Herein, we present the case of a patient with oligometastatic liver recurrence of BRCA2-mutated PDAC following a curative-intent resection. Through a combination of systemic chemotherapy, metastasectomy, radiotherapy, and subsequent targeted therapy wit...
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.1c00653
British Journal of Cancer, Published online: 26 October 2021; doi:10.1038/s41416-021-01580-xA risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO
Effective in situ cancer vaccines require both a means of tumor cell death and a source of adjuvant to activate local dendritic cells. Studies have shown that the use of radiotherapy (RT) to induce tumor cell death and anti-CD40 to activate dendritic cells can result in in situ vaccination in animal models. Here, investigations are carried out on potential strategies to enhance such in situ vaccination. Strategies investigated include the use of smart immunogenic biomaterials (IBM) loaded with anti-CD40 in different tumor types including immunologically cold tumors like pancreatic and prostate tumors. The use of downstream...
Conclusion: Modulating B cell development, neoangiogenesis and fibrosis, and SDF-1/CXCL12 may play a role in IgG4-RD. The higher levels observed in IgG4-RD, as compared to SSj, which closely mimics the disease, can be related to a different pattern of lesions, with prevalent fibrosis seen in IgG4-RD. Taken together, these findings suggest that drugs acting on the CXCL12/CXCR4/CXCR7 axis may affect IgG4-RD.